Place · Level 3
Fish Oil · EPA / DHA Supplement
全球销售第一的补剂之一 · 机制清楚 · 但 RCT 证据近 5 年大翻转 · 食物胜过药丸的经典案例
Last updated
Story path
Chapter 1
Three forms + freshness
Three forms + freshness
'Fish oil' isn't one thing — the forms on the market differ enormously, and the form directly drives absorption and safety.
① Natural triglyceride (TG / rTG, re-esterified) — the original form inside the fish
Highest absorption (~70%)Mid-to-high pricerTG (re-esterified) — purified through the EE step then re-attached to a TG backbone, giving high purity + high absorption
② Ethyl ester (EE) — the common output of industrial distillation
Glycerol on the TG is swapped for ethanolAbsorption 30-50% lower than TG (Dyerberg 2010)Works poorly on an empty stomach; needs a fatty mealMost cheap fish oils and REDUCE-IT's icosapent ethyl (Vascepa) are EE
③ Phospholipid-bound — krill oil
EPA / DHA covalently attached to phospholipids (PC)Theoretically the best absorption, but each capsule carries little EPA + DHAMost expensive; astaxanthin antioxidant is a byproduct
The point: TOTOX (oxidation level)
TOTOX = 2 × peroxide value (PV) + anisidine value (AV)TOTOX < 26 is the international standard (GOED + EU)Real-world testing: in the Albert 2015 NZ study ~83% exceeded the peroxide value (PV) limit, and ~50% exceeded the TOTOX limitOxidized fish oil isn't just ineffective — it's actively pro-oxidant, and produces nausea, fishy burps, and elevated liver enzymes
How to choose:
TOTOX < 10 is excellentLook for IFOS / GOED certificationRefrigerate after opening; use within 2-3 monthsStrong fishy taste or nausea → throw it out immediatelyForm preference: rTG > TG > EE
① Natural triglyceride (TG / rTG, re-esterified) — the original form inside the fish
Highest absorption (~70%)Mid-to-high pricerTG (re-esterified) — purified through the EE step then re-attached to a TG backbone, giving high purity + high absorption
② Ethyl ester (EE) — the common output of industrial distillation
Glycerol on the TG is swapped for ethanolAbsorption 30-50% lower than TG (Dyerberg 2010)Works poorly on an empty stomach; needs a fatty mealMost cheap fish oils and REDUCE-IT's icosapent ethyl (Vascepa) are EE
③ Phospholipid-bound — krill oil
EPA / DHA covalently attached to phospholipids (PC)Theoretically the best absorption, but each capsule carries little EPA + DHAMost expensive; astaxanthin antioxidant is a byproduct
The point: TOTOX (oxidation level)
TOTOX = 2 × peroxide value (PV) + anisidine value (AV)TOTOX < 26 is the international standard (GOED + EU)Real-world testing: in the Albert 2015 NZ study ~83% exceeded the peroxide value (PV) limit, and ~50% exceeded the TOTOX limitOxidized fish oil isn't just ineffective — it's actively pro-oxidant, and produces nausea, fishy burps, and elevated liver enzymes
How to choose:
TOTOX < 10 is excellentLook for IFOS / GOED certificationRefrigerate after opening; use within 2-3 monthsStrong fishy taste or nausea → throw it out immediatelyForm preference: rTG > TG > EE
机制 · 吸收和氧化其实是同一根分子的两头
买哪种形式和新不新鲜看着是两件不相干的事, 其实都落在同一根分子上。走一遍就明白了。一 · 乙酯型 (EE) 为什么吸收得慢
脂肪不能被肠道直接吸收。油进小肠后, 先被胆汁打散成极细的油滴, 再由胰腺分泌的脂肪酶把脂肪酸从骨架上一根根剪下来; 剪下来的脂肪酸才穿得过肠壁细胞。
天然甘油三酯型 (TG / rTG) 的骨架是甘油, 这正是胰脂肪酶天天在处理的形状, 剪起来顺手。乙酯型 (EE) 是工业蒸馏的产物: 骨架上的甘油被换成了乙醇。同一把剪刀去剪这个接口, 慢得多——EPA 和 DHA 还没被解下来, 食糜已经往下游走了。
所以空腹吃更吃亏不是玄学。空腹时胆汁分泌少、胰脂肪酶也没被叫醒, 本来就慢的这一刀更慢; 配一顿带油的饭, 等于把这道工序叫开工。rTG 的思路则是: 先走一遍乙酯型这道工序把杂质纯化掉, 再把脂肪酸装回甘油骨架——纯度和好剪, 两件事都要。
二 · 鱼油为什么放着放着就废了
omega-3 之所以有用, 靠的是链上那些双键 (下一幕讲它们怎么起作用); 而它之所以脆, 靠的也是同一批双键。
夹在两个双键中间的那个碳, 手上的氢特别松。空气里的氧一来就把氢拽走, 这根链于是变成一个带着未配对电子的残缺分子, 转身去抢隔壁那根链上的氢——一根被氧化的链会去点燃下一根。所以氧化不是匀速变坏, 而是一旦起头就成串地塌。
这条链反应的终产物是一批小分子醛。它们就是:
你闻到的那股哈喇味打嗝返上来的腥吃完那阵反胃
所以那句腥味重就扔掉, 不是嫌弃口感——你的鼻子读到的就是氧化产物本身。 冷藏、避光、棕色瓶、开瓶后尽快喝完, 全都是在压住这条链反应起头的速度: 温度和光都是它的点火源。
DHA 链上的双键比 EPA 还多, 所以高 DHA 的配方天生更娇气。这也是为什么它被做成密封的软胶囊, 而不是敞口的糖浆。
Reading the label · actual dose
The most common label trap on a fish-oil bottle is the '1000 mg fish oil' claim:1000 mg of fish oil ≠ 1000 mg of EPA + DHAA typical '1000 mg fish oil' cap contains only ~180 mg EPA + 120 mg DHA = 300 mg ω-3To reach the AHA's 'EPA + DHA 1 g/day' target you need 3-4 caps'Concentrated high-potency' caps (60-80% omega-3) deliver 700-800 mg ω-3 per cap
Target dose reference (AHA / GOED):
General prevention (≥ 2 fatty-fish meals/week): no supplement neededCV secondary prevention / high TG: EPA + DHA 1-2 g/dayREDUCE-IT therapeutic (high TG + atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease.): icosapent ethyl 4 g/day (EPA-only)Pregnancy DHA: ≥ 200 mg/day (fetal brain development)UL: FDA sets the daily omega-3 ceiling at 3 g (from supplements); large doses extend bleeding time
Fish oil and anticoagulation boundaries:
Healthy adults at 1-2 g/day: no effect on INR / bleedingStopping 7 days before surgery is a conservative recommendationOn warfarin / antiplatelets: tell your physician; usually a minor issueReal bleeding impact appears only at chronic >4 g/day
Chapter 2
EPA vs DHA · different jobs
EPA vs DHA · different jobs
EPA and DHA differ by only two carbons and one double bond, but they do completely different jobs in the body.
EPA (20:5, eicosapentaenoic acid) — anti-inflammatory messenger:
Precursor → resolvins + protectins (endogenous anti-inflammatory mediators)Competes with AA (arachidonic acid, ω-6) for COX/LOX enzymes, lowering pro-inflammatory prostaglandinsHigh-concentration EPA RCTs show reductions in triglycerides + cardiovascular eventsREDUCE-IT (NEJM 2018) used pure EPA (icosapent ethyl) at 4 g/day → MACE ↓ 25%
DHA (22:6, docosahexaenoic acid) — membrane material:
Retina ~50% DHA (rod outer segment)Brain gray matter 15-20% DHACritical lipid for membrane fluidity and receptor functionDrives fetal brain development + infant visual maturation (see `fats-omega-3/membrane` Level-4 animation)
Can the two interconvert?
EPA → DHA: partially possible (full chain ALA → EPA → DPA → DHA)DHA → EPA: partially possible (retro-conversion)Both efficiencies are low — if you want one specifically, supplement that form directly
So:
Anti-inflammatory / TG-lowering / CV secondary prevention → prefer high-EPA formulasPregnancy / infants / brain-health focus → DHA can't be skippedBalanced supplements (~EPA:DHA = 1.5:1 to 2:1) suit general use'Pure EPA' formulas belong to REDUCE-IT-style indications, not everyday wellness
EPA (20:5, eicosapentaenoic acid) — anti-inflammatory messenger:
Precursor → resolvins + protectins (endogenous anti-inflammatory mediators)Competes with AA (arachidonic acid, ω-6) for COX/LOX enzymes, lowering pro-inflammatory prostaglandinsHigh-concentration EPA RCTs show reductions in triglycerides + cardiovascular eventsREDUCE-IT (NEJM 2018) used pure EPA (icosapent ethyl) at 4 g/day → MACE ↓ 25%
DHA (22:6, docosahexaenoic acid) — membrane material:
Retina ~50% DHA (rod outer segment)Brain gray matter 15-20% DHACritical lipid for membrane fluidity and receptor functionDrives fetal brain development + infant visual maturation (see `fats-omega-3/membrane` Level-4 animation)
Can the two interconvert?
EPA → DHA: partially possible (full chain ALA → EPA → DPA → DHA)DHA → EPA: partially possible (retro-conversion)Both efficiencies are low — if you want one specifically, supplement that form directly
So:
Anti-inflammatory / TG-lowering / CV secondary prevention → prefer high-EPA formulasPregnancy / infants / brain-health focus → DHA can't be skippedBalanced supplements (~EPA:DHA = 1.5:1 to 2:1) suit general use'Pure EPA' formulas belong to REDUCE-IT-style indications, not everyday wellness
分工细节 · 两条链各自的去向
EPA 和 DHA 在化学上只差 2 个碳和 1 个双键, 但身体里的工作完全不同。EPA (20:5, 二十碳五烯酸)——抗炎信使:
前体 → resolvins 加 protectins (内源抗炎介质)与 AA (花生四烯酸, ω-6) 竞争 COX/LOX 酶, 减少促炎前列腺素高浓度 EPA RCT 显示降甘油三酯加心血管事件REDUCE-IT (NEJM 2018) 用纯 EPA (icosapent ethyl) 4 g/天, MACE 减少 25%
DHA (22:6, 二十二碳六烯酸)——膜建材:
视网膜约 50% DHA (杆细胞外节)脑灰质 15–20% DHA是膜流动性和受体功能的关键脂孕期胎儿脑神经发育加婴儿视觉发育主要靠 DHA (详见 `fats-omega-3/membrane` Level 4 动画)
它们之间能否相互转换?
EPA → DHA: 部分可以 (经 ALA → EPA → DPA → DHA 完整链)DHA → EPA: 部分可以 (回返转化)效率都不高, 想要某一个就直接补该形式
所以:
抗炎、降 TG / 心血管二级预防 → 优选高 EPA 配方孕期、婴儿、脑健康关注 → DHA 不能少平衡型补剂 (~ EPA:DHA = 1.5:1 到 2:1) 适合一般使用最纯 EPA补剂用在 REDUCE-IT 类适应症, 不是日常保健
机制 · 一层软膜, 和一场抢座位
上一页说 DHA 是建材、EPA 是信使。这两句话背后各有一条完整的物理过程, 走完你就能自己推演别的情况了。DHA · 那根弯了六下的链, 撑起一层软膜
饱和脂肪的链是直的。一根挨一根, 能像码筷子那样堆得整整齐齐、堆得很紧。链上每多一个双键, 就多一个折不回去的弯。
DHA 弯了六下。它插进细胞膜里, 周围那一片就再也码不整齐、挤不密实——那层膜因此一直是软的、能变形的。
为什么偏偏是视网膜和灰质需要这层软膜:
视杆细胞的外节是一摞极薄的膜盘。光打进来的一瞬间, 膜上负责接光的那个蛋白必须立刻改变形状, 才能把信号往下递。膜要是硬的, 这个变形就得顶着阻力做, 慢一拍。DHA 撑起的软膜, 等于给这个动作腾出了余地。大脑灰质的突触膜同理: 受体和离子通道全都嵌在膜里, 它们工作的方式就是改变形状。膜的软硬直接决定这些蛋白改形状要费多大劲。
所以 DHA 不是对眼睛好、对脑子好这种模糊说法——它是这两个器官里那些高速变形的蛋白脚下踩的地板。地板软, 动作才快得起来。
EPA · 抢一个口袋的位子
先弄清炎症信号是从哪来的。
平时, 花生四烯酸 (AA, 一种 ω-6 长链脂肪酸) 并不游在血里, 而是挂在细胞膜的磷脂上。一有刺激, 一种酶把它从膜上剪下来, 交给 COX 和 LOX 两套酶加工成前列腺素、白三烯。你感到的红、肿、热、痛, 就是这批分子干的活。
EPA 的链长和形状跟 AA 太像了, 像到能坐进同一套酶的那个口袋。于是两件事同时发生:
EPA 占着口袋的时候, 那个酶分子腾不出手去处理 AA。 同样的刺激, 做出来的促炎分子少了一批。就算被加工出来, EPA 的产物本身也更温和。
把两条线接起来 · 膜既是建材, 也是弹药库
注意上一段里那个不起眼的细节——AA 是从膜上剪下来的。EPA 和 DHA 平时也一样挂在膜上。
于是关键的一环出现了: 刺激来临那一刻, 酶从膜上剪下来的是 AA 还是 EPA, 取决于你的膜是用什么砌的。 你吃进去的 omega-3 有没有真的换进膜里, 决定的不只是膜软不软, 还决定了发信号时手边的原料是哪一种。
这也解释了一个常被当成玄学的现象: 鱼油要连着吃上几个月才谈得上效果。换膜是慢的——细胞得一点点把新脂肪酸装进磷脂, 吃一顿改变不了库存。
还有比少发炎更主动的一层
炎症的结束, 不是等它自己烧完。身体会另发一套收尾信号: 把清理残局的细胞叫过来、把碎片吃掉、让血管恢复原状。这是一个要主动启动的程序。
EPA 和 DHA 正是这套收尾分子 (resolvins 和 protectins) 的原料。
所以原料不足的后果不是炎症烧得更旺, 而是收不了尾——该结束的时候结束不掉, 拖成低烧一样长期存在的那种。这两种失败长得完全不一样, 分清楚它们, 你就能看懂为什么抗炎这个词在补剂广告里常常被用错。
RCT pivot · weak signal in general population
The fish-oil RCT story is one of the most dramatic pivots in modern nutrition medicine.2002-2010 (the optimistic era): GISSI-Prevenzione, JELIS, and other early RCTs showed reduced recurrence in post-MI patients taking fish oil.
2018-2020 (major recalibration): large, rigorous RCTs overturned the general-population benefit.
VITAL trial (NEJM 2019, N = 25,871, 5.3 yr):
Healthy adults on EPA + DHA 1 g/day vs placeboPrimary CV / cancer endpoints: no significant benefitSecondary endpoint: total MI ↓ 28% (HR 0.72, 95% CI 0.59–0.90, statistically significant)Black subgroup MI ↓ 77% (striking but needs replication)
ASCEND trial (NEJM 2018, N = 15,480, 7.4 yr):
Diabetic adults with no CV history on ω-3 1 g/daySerious vascular events: no significant benefit (RR 0.97, P=0.55)
STRENGTH trial (JAMA 2020, N = 13,078):
High-CV-risk patients on carboxylic-acid-form EPA + DHA 4 g/dayStopped early: no benefit, plus atrial fibrillation up 70%Stark contrast with REDUCE-IT's pure-EPA 4 g
REDUCE-IT vs STRENGTH controversy:
Same dose (4 g), similar high-CV-risk populationREDUCE-IT positive (pure EPA), STRENGTH negative (EPA + DHA)Three explanations: EPA-without-DHA is the key driver (mechanism hypothesis); REDUCE-IT's mineral-oil placebo was harmful (FDA investigated, partially supported); the truth lies betweenThis is why icosapent ethyl was FDA-approved while other fish-oil formulations were not
Current consensus:
Healthy population using fish oil for CV prevention: weak evidenceHigh TG (> 500 mg/dL): first-line indicationVery-high CV risk + high TG: icosapent ethyl (Vascepa) by prescription≥ 2 fatty-fish meals/week (salmon / sardines / mackerel): stronger evidence than any supplement (DGAC + AHA)
nicholls-2020-strengthascend-2018
Chapter 3
Food vs pill
Food vs pill
'Eat fish or take fish oil' is a question with a data-driven answer.
Typical fatty-fish ω-3 content (per 100 g cooked):
Salmon (Atlantic farmed): 1.8-2.5 g EPA + DHASardines (oil-packed): 1.4-1.5 gMackerel: 1.0-2.7 g (large seasonal variation)Cod: 0.2-0.3 g (lean fish, low)Tuna (deep-sea canned): 0.2-0.5 g (water-packed loses some)Trout: 0.8-1.5 g
For comparison: one 'standard' fish-oil cap is ~0.3 g ω-3, so two 100 g salmon meals/week ≈ 20 caps/week = 3 caps/day.
But 'eating fish' is more than ω-3:
High-quality protein (~20-25 g / 100 g)Vitamin D (fatty fish is one of the few natural D-rich sources)Iodine (marine fish)Selenium (marine fish + shellfish)Vitamin B12Satiety, substituting for red and processed meat
Multiple epidemiological and RCT meta-analyses show that consuming fatty fish vs taking ω-3 capsules gives stronger cardiovascular protection. This is the food matrix effect: many bioactives in a whole food acting in synergy, not a single isolated compound.
Practical:
2-3 fatty-fish meals/week (≥ 150 g each): most people get adequate ω-3 from food, no supplement neededDon't eat fish / vegan: consider algal oil for DHA, 200-500 mg/dayPregnancy: pick low-mercury species (salmon / sardine / trout); limit large predatory fish (shark / swordfish / bigeye tuna)Liver disease or on anticoagulants: discuss with a clinician
Typical fatty-fish ω-3 content (per 100 g cooked):
Salmon (Atlantic farmed): 1.8-2.5 g EPA + DHASardines (oil-packed): 1.4-1.5 gMackerel: 1.0-2.7 g (large seasonal variation)Cod: 0.2-0.3 g (lean fish, low)Tuna (deep-sea canned): 0.2-0.5 g (water-packed loses some)Trout: 0.8-1.5 g
For comparison: one 'standard' fish-oil cap is ~0.3 g ω-3, so two 100 g salmon meals/week ≈ 20 caps/week = 3 caps/day.
But 'eating fish' is more than ω-3:
High-quality protein (~20-25 g / 100 g)Vitamin D (fatty fish is one of the few natural D-rich sources)Iodine (marine fish)Selenium (marine fish + shellfish)Vitamin B12Satiety, substituting for red and processed meat
Multiple epidemiological and RCT meta-analyses show that consuming fatty fish vs taking ω-3 capsules gives stronger cardiovascular protection. This is the food matrix effect: many bioactives in a whole food acting in synergy, not a single isolated compound.
Practical:
2-3 fatty-fish meals/week (≥ 150 g each): most people get adequate ω-3 from food, no supplement neededDon't eat fish / vegan: consider algal oil for DHA, 200-500 mg/dayPregnancy: pick low-mercury species (salmon / sardine / trout); limit large predatory fish (shark / swordfish / bigeye tuna)Liver disease or on anticoagulants: discuss with a clinician
含量表 · 一顿鱼抵多少粒胶囊
吃鱼还是吃鱼油是一个有数据答案的问题。典型脂肪鱼 ω-3 含量 (100 g 熟食):
鲑鱼 (大西洋养殖): 1.8–2.5 g EPA 加 DHA沙丁鱼 (罐头, 含油): 1.4–1.5 g鲭鱼 (mackerel): 1.0–2.7 g (季节差大)鳕鱼 (cod): 0.2–0.3 g (瘦肉鱼少)金枪鱼 (深海罐头): 0.2–0.5 g (淡水鱼罐头损失)鳟鱼: 0.8–1.5 g
比较一下: 1 粒标准鱼油约 0.3 g ω-3, 一周 2 次 100 g 鲑鱼约等于 20 粒/周 = 3 粒/天。
但吃鱼远不止 ω-3:
优质蛋白质 (~ 20–25 g / 100 g)维 D (脂肪鱼是少有的天然 D 富集源)碘 (海鱼)硒 (海鱼加龙虾)维 B12饱腹感, 替代红肉、加工肉
多个流行病学和 RCT meta-analysis 显示, 食用脂肪鱼 vs 补 ω-3 胶囊对心血管的保护, 前者效应更强。这是食物矩阵效应 (food matrix effect): 整食物里多种生物活性物协同, 不是单一成分。
实操:
每周 2–3 次脂肪鱼 (单次 ≥ 150 g): 多数人能从中拿到充足 ω-3, 不需要补剂不吃鱼或素食: 考虑藻油 (algal oil) 补 DHA, 200–500 mg/天孕期: 由于汞担忧, 选低汞鱼 (鲑、沙丁、鳟); 大型掠食鱼 (鲨、旗鱼、大眼金枪鱼) 限量肝病或服抗凝药: 与医生讨论
机制 · 为什么整条鱼比一粒胶囊强
食物矩阵效应这个词常被当成一句好听的托词。它其实指得很具体, 拆开是三件能各自走通的事。一 · 鱼把 omega-3 送进了它最容易被吸收的场合
第一幕讲过, 脂肪要先被胆汁打散、被胰脂肪酶剪开, 才穿得过肠壁。这道工序的效率高度依赖场合。
鱼肉里的 EPA 和 DHA 本来就装在磷脂和甘油三酯里, 跟着一整顿有脂肪、有蛋白的饭进小肠。胆汁被叫足了, 脂肪酶也醒着——这是那道剪切工序最顺的条件。空腹吞一粒乙酯型胶囊, 恰恰是同一道工序最差的条件。
同样标着相同毫克数的 omega-3, 真正进到血里的量并不一样。
二 · 鱼把保护 omega-3 的东西和 omega-3 装在了同一块肉里
多不饱和脂肪最怕的就是被氧化 (第一幕那条链反应)。而海鱼同时是硒的主要来源之一。
硒在体内会被装进一类硒蛋白, 其中一类的本职工作就是把已经生成的脂质过氧化物拆掉——也就是掐断那条会成串塌下去的链反应。鱼等于把易燃品和灭火器打包在一起卖。 胶囊里通常只有易燃品, 所以厂家得另外加抗氧化剂、密封、避光。
同一块鱼里还有维生素 D。它和 omega-3 都是脂溶性的, 靠同一批胆盐微团被运过肠壁——这一餐的脂肪同时把两样都带了过去。
三 · 吃鱼的那一餐, 顶掉了原本要吃的东西
这一条是最容易被漏掉、却最能解释证据分歧的一条。
观察性研究里的吃鱼的人, 是用鱼换掉了一餐别的——往往是红肉或加工肉。测到的效应里, 一部分来自鱼带来了什么, 一部分来自那一餐没吃什么。补剂试验里的吃胶囊的人, 是在原本的饮食之上加了一粒。什么都没被顶掉。
所以这两类研究问的根本不是同一个问题: 一个问换掉一餐会怎样, 一个问多加一点 omega-3 会怎样。它们答案不同, 不是矛盾, 是设计不同。
这就是为什么多吃鱼的证据一直比补鱼油的证据强, 而且以后大概率还是这样。 补剂能复制的只有那一个分子; 复制不了吸收的场合、复制不了同行的硒和维生素 D, 更复制不了被顶掉的那块加工肉。
Mercury & microplastics
Real risk considerations when eating fish:① Methylmercury
Biomagnifies — long-lived, large predatory fish carry the highest mercuryHigh risk: shark, swordfish, marlin, bigeye tuna, tilefish, Pacific king mackerelLow risk: salmon, sardines, mackerel (Atlantic, NOT king mackerel), trout, shrimp, scallops, tilapiaEPA-DHA vs mercury net: Mozaffarian & Rimm 2006 concluded benefit > risk for most adults (pregnant women, children under 5, and women of childbearing age need particular caution)
② POPs (persistent organic pollutants — PCB / dioxins)
Concentrate in farmed fish (feed-driven accumulation)Modern certified fish oil is distilled and largely free of PCB / mercury'Purity' labels: IFOS 5-star certification is meaningful
③ Microplastics + PFAS
Microplastics and perfluoroalkyl substances have been detected in most fish (and in water + salt — not exclusive to fish)Health impact is still under study, but not a reason to stop eating fish
④ Fish-oil oxidation (covered in the earlier scene): a far more common clinical 'supplement quality' issue than mercury or PCB.
Pregnancy / lactation recommendations (FDA + EPA, 2021 revision):
2-3 servings (~ 8-12 oz / 230-340 g) of low-mercury fish per weekAvoid: shark, swordfish, marlin, orange roughy, tilefish (Gulf of Mexico), bigeye tuna, king mackerelLimit: yellowfin tuna (1 serving/week), canned white tuna'Eat no fish at all' is actively NOT recommended by FDA + EPA — DHA is too critical for the fetus
Summary: 2-3 low-mercury fatty-fish meals per week + no supplement is the strongest current evidence-based strategy for the average adult, and this clarity has only sharpened after the recent wave of RCT reversals.
Chapter 4
Plant ω-3 (ALA) · incomplete sub
Plant ω-3 (ALA) · incomplete sub
Vegetarian ω-3 substitution is incomplete — the most commonly oversimplified topic in nutrition science.
ALA (α-linolenic acid, 18:3 ω-3) sources:
Flaxseed oil: 53-57% ALAChia seeds: 18% ALAWalnuts: 9% ALAHemp seeds: 22% ALASoybean / canola oil: 7-10% ALA
Key point: endogenous ALA → EPA → DHA conversion is very low
ALA → EPA: 5-8% (women slightly higher, estrogen-related)EPA → DHA: 0.5-5%Total ALA → DHA: 0.1-4%
This means a fully fish-free diet relying only on flaxseed oil produces noticeably low blood EPA / DHA — but it doesn't mean 'fully deficient'; ALA itself is an essential fatty acid. Long-term vegetarians' blood EPA / DHA runs 20-50% lower than fish-eaters', but CV event rates don't track that proportionally, possibly because the overall diet pattern is healthier.
Algal oil is the true vegan source of DHA / EPA:
DHA / EPA extracted from microalgae (the original ω-3 source that fish eat) is biochemically equivalent to fish oilTypical product: 200-500 mg DHA per capsuleCost is higher (about 3-5× fish oil)Strongly recommended for vegan women in pregnancy and lactation
ω-6 / ω-3 ratio:
Modern Western diet 15-20 : 1Estimated evolutionary ratio 1-4 : 1'High ω-6 is the source of inflammation' is a popular claim but the actual evidence is weak: RCTs replacing saturated fat with ω-6 (linoleic acid) consistently show lower LDL and lower CV eventsThe point is not 'lower ω-6' — it's 'absolutely increase ω-3'Don't agonize over ω-6; focus on total ω-3 intake instead
ALA (α-linolenic acid, 18:3 ω-3) sources:
Flaxseed oil: 53-57% ALAChia seeds: 18% ALAWalnuts: 9% ALAHemp seeds: 22% ALASoybean / canola oil: 7-10% ALA
Key point: endogenous ALA → EPA → DHA conversion is very low
ALA → EPA: 5-8% (women slightly higher, estrogen-related)EPA → DHA: 0.5-5%Total ALA → DHA: 0.1-4%
This means a fully fish-free diet relying only on flaxseed oil produces noticeably low blood EPA / DHA — but it doesn't mean 'fully deficient'; ALA itself is an essential fatty acid. Long-term vegetarians' blood EPA / DHA runs 20-50% lower than fish-eaters', but CV event rates don't track that proportionally, possibly because the overall diet pattern is healthier.
Algal oil is the true vegan source of DHA / EPA:
DHA / EPA extracted from microalgae (the original ω-3 source that fish eat) is biochemically equivalent to fish oilTypical product: 200-500 mg DHA per capsuleCost is higher (about 3-5× fish oil)Strongly recommended for vegan women in pregnancy and lactation
ω-6 / ω-3 ratio:
Modern Western diet 15-20 : 1Estimated evolutionary ratio 1-4 : 1'High ω-6 is the source of inflammation' is a popular claim but the actual evidence is weak: RCTs replacing saturated fat with ω-6 (linoleic acid) consistently show lower LDL and lower CV eventsThe point is not 'lower ω-6' — it's 'absolutely increase ω-3'Don't agonize over ω-6; focus on total ω-3 intake instead
机制 · 改造线堵在哪两处
把 ALA 变成 EPA、再变成 DHA, 是一条要过好几道工序的流水线。它慢, 慢在两个很具体的地方。走完这两处, 你就能自己解释为什么亚麻籽油怎么加量都补不上 DHA。堵点一 · 开双键的那台机器是和 ω-6 共用的
给一根脂肪链开出一个新双键这件事, 靠的是一类叫去饱和酶的酶。这条线上打头的那台叫 Δ6-去饱和酶 (它的基因名是 FADS2)。
麻烦在于: 它同时也是 ω-6 那条线的第一道工序。你饭里的亚油酸 (来自大豆油、玉米油、葵花籽油这些最常见的食用油) 要变成花生四烯酸, 走的是同一台机器。
而现代饮食里亚油酸的量, 通常远远多过 ALA。两种原料在同一个窗口前排队, 数量占优的那一方把窗口占了大半, ALA 只能慢慢往前挪。这就是为什么单纯多吃亚麻籽油, 血里的 EPA 也涨得很有限——不是原料不够, 是窗口不够。
堵点二 · 最后一步 DHA 要绕道
身体没有一台能在已经很长的那根链上直接再开一个双键的机器。要做出 DHA, 它必须绕:
先把链接得比目标还长在这根加长版上开双键再把整根链送进细胞里另一个车间 (过氧化物酶体)在那里剪掉两个碳, 才得到 DHA, 然后运回来
多绕一圈, 还要跨车间。所以整条线上最后这一步掉得最狠。 转成 EPA 已经不容易、转成 DHA 更难, 这不是两个并列的坏消息, 是同一条线越靠后越窄。
女性转换率略高, 也是同一条线上的事
雌激素会把这条线上的酶往上调一点。往孕期看就说得通了: 胎儿的脑和视网膜正是最吃 DHA 的地方, 而供货只能来自母体。身体把这条窄路在最需要的时候拓宽了一点点。
所以实际怎么办
亚麻籽、核桃、奇亚籽照吃。ALA 本身就是必需脂肪酸, 而且这些食物带来的远不止 ALA。但如果你的目标是把血里的 DHA 提上去, 别在改造线上使劲——那是在跟一条结构性变窄的通道较劲。直接给成品: 藻油。藻油和鱼油里的 DHA 在生化上是同一个分子。区别只在它来自食物链的哪一环: 微藻是原产地, 鱼只是中间的仓库。
转换率与来源 · 具体数字, 以及 ω-6 比例的争论
素食者的 ω-3 替代不全——这是营养学最常被简化错的话题。ALA (α-亚麻酸, 18:3 ω-3) 来源:
亚麻籽油: 53–57% ALA奇亚籽: 18% ALA核桃: 9% ALA大麻籽: 22% ALA大豆油 / canola 油: 7–10% ALA
关键: ALA → EPA → DHA 的内源转换率极低
ALA → EPA: 5–8% (女性略高, 雌激素相关)EPA → DHA: 0.5–5%ALA → DHA 总转换: 0.1–4%
这意味着完全不吃鱼加仅靠亚麻籽油, 血 EPA / DHA 显著低; 但不代表完全缺——ALA 本身也是必需脂肪酸。长期素食者血 EPA / DHA 比鱼食者低 20–50%, 但心血管事件率没有相应升高, 可能因为饮食模式整体更健康。
藻油 (algal oil) 是素食者真正的 DHA / EPA 来源:
微藻 (鱼吃藻才有 ω-3) 提取的 DHA / EPA 与鱼油生化等价典型产品: 200–500 mg DHA / 胶囊价格较高 (约鱼油的 3–5 倍)但孕期、哺乳期素食者强烈推荐
ω-6 / ω-3 比例:
现代西方饮食 15–20 : 1进化期估计 1–4 : 1ω-6 过量是炎症根源是热门说法, 但实际证据弱: 替换饱和脂肪为 ω-6 (亚油酸) 的 RCT 都显示降 LDL 加降 CV 事件关键不是降 ω-6, 而是绝对增加 ω-3不必为 ω-6 焦虑, 直接关注 ω-3 总摄入
What ALA itself does
ALA itself (even without conversion to EPA / DHA) is an essential fatty acid — the body can't synthesize it. Its roles:1. Energy substrate: like other fatty acids, β-oxidized for energy
2. A small fraction joins membrane phospholipids: contributing to fluidity
3. Cardiovascular evidence (independent of EPA/DHA): the Sacks AHA 2017 review shows a positive (though weak) correlation between high ALA intake and lower CV events; PREDIMED-Plus + several cohorts show 1-2 g/day ALA correlates with ~10% lower all-cause mortality; mechanism partially via anti-arrhythmic effects
4. Modest inflammation marker improvement (limited evidence): high-ALA diet produces small drops in C-reactive protein: A liver protein that rises with inflammation — a common blood marker for 'is the body inflamed'. / interleukin-6: A pro-inflammatory signal molecule (cytokine) released by immune cells during inflammation.
Practical recommendations (vegetarian or no fish):
1-2 tablespoons of ground flaxseed daily (ground, not whole — whole seeds pass through largely intact) ≈ 2-3 g ALA1 handful of walnuts (28 g) ≈ 2.5 g ALA1-2 tablespoons of chia seeds ≈ 5 g ALAAdd algal DHA 200-500 mg/day (especially in pregnancy, lactation, and children under 5)Don't cook with flaxseed oil — PUFAs oxidize rapidly under heat
Common wrong claims to flag:
'Flaxseed oil equals fish oil': wrong — conversion is insufficient'Pure vegan needs no supplements': B12, DHA, and often iron / zinc all deserve attention'ω-3:ω-6 must be tuned to 1:1 for health': no evidence supports this extreme
Chapter 5
Other indications · tiered evidence
Other indications · tiered evidence
Beyond cardiovascular disease, fish oil / EPA + DHA has other evidence-based indications, with widely varying evidence strength.
Strong evidence (A grade):
High triglycerides (TG > 500 mg/dL): EPA + DHA 2-4 g/day lowers TG 20-50%Icosapent ethyl (Vascepa) 4 g + statin in high TG + atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease. patients: MACE ↓ 25% (REDUCE-IT)Pregnancy DHA ≥ 200 mg/day: fetal brain + visual development, ACOG recommended
Moderate evidence (B grade):
Rheumatoid arthritis (RA): 3-4 months of omega-3 supplementation reduced morning stiffness (SMD -0.43) and NSAID consumption (SMD -0.40) across 17 RCTs (Goldberg 2007 meta). ⚠️ That '3-4' is the DURATION in the paper — it publishes no g/day figureMajor depression as adjunct: Liao 2019 meta found benefit for formulations with EPA ≥ 60% of the blend at an EPA dose of ≤ 1 g/day; DHA-pure and DHA-major formulations showed none. Note the direction of that dose limit — more is not the lever hereDry eye: DREAM trial 2018 showed no significant benefit (earlier small studies had been optimistic)
Disputed / weak evidence:
Cognitive function / Alzheimer's prevention: most RCTs negative (Yurko-Mauro 2010 with DHA alone showed a little, but the ADCS DHA trial — Quinn 2010 JAMA — and VITAL were negative)Pediatric ADHD: Bloch 2011 meta shows a small effect (SMD ~0.31), not first-lineMacular degeneration: AREDS2 showed no additional benefit from added ω-3Exercise recovery: limited evidence for reducing muscle sorenessAllergy / asthma: early maternal-infant supplementation may slightly reduce offspring allergy risk
No / negative evidence:
Cancer prevention: VITAL negativeDiabetes prevention: ASCEND negative'Make you smarter' / 'anti-aging': marketing claims, no RCT support
So the real role of fish oil:
Adjunct for specific patients (high TG / RA / specific MDD subtypes)ω-3 source for those who don't eat fishPregnancy DHA supplementNot a universal 'wellness for healthy people' supplement
Strong evidence (A grade):
High triglycerides (TG > 500 mg/dL): EPA + DHA 2-4 g/day lowers TG 20-50%Icosapent ethyl (Vascepa) 4 g + statin in high TG + atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease. patients: MACE ↓ 25% (REDUCE-IT)Pregnancy DHA ≥ 200 mg/day: fetal brain + visual development, ACOG recommended
Moderate evidence (B grade):
Rheumatoid arthritis (RA): 3-4 months of omega-3 supplementation reduced morning stiffness (SMD -0.43) and NSAID consumption (SMD -0.40) across 17 RCTs (Goldberg 2007 meta). ⚠️ That '3-4' is the DURATION in the paper — it publishes no g/day figureMajor depression as adjunct: Liao 2019 meta found benefit for formulations with EPA ≥ 60% of the blend at an EPA dose of ≤ 1 g/day; DHA-pure and DHA-major formulations showed none. Note the direction of that dose limit — more is not the lever hereDry eye: DREAM trial 2018 showed no significant benefit (earlier small studies had been optimistic)
Disputed / weak evidence:
Cognitive function / Alzheimer's prevention: most RCTs negative (Yurko-Mauro 2010 with DHA alone showed a little, but the ADCS DHA trial — Quinn 2010 JAMA — and VITAL were negative)Pediatric ADHD: Bloch 2011 meta shows a small effect (SMD ~0.31), not first-lineMacular degeneration: AREDS2 showed no additional benefit from added ω-3Exercise recovery: limited evidence for reducing muscle sorenessAllergy / asthma: early maternal-infant supplementation may slightly reduce offspring allergy risk
No / negative evidence:
Cancer prevention: VITAL negativeDiabetes prevention: ASCEND negative'Make you smarter' / 'anti-aging': marketing claims, no RCT support
So the real role of fish oil:
Adjunct for specific patients (high TG / RA / specific MDD subtypes)ω-3 source for those who don't eat fishPregnancy DHA supplementNot a universal 'wellness for healthy people' supplement
机制 · 大剂量鱼油怎么把甘油三酯拉下来
降甘油三酯是鱼油证据最硬的一条, 但站内别处只给了结论。它的过程发生在肝脏, 值得走一遍——走完你会顺带明白, 为什么这件事需要的量远高于日常保健量。先弄清血里的甘油三酯是从哪来的
空腹抽血量到的甘油三酯, 大部分并不是你刚吃进去的那口油, 而是肝脏自己打包发出来的。
肝细胞把脂肪酸组装成甘油三酯, 装进一个货舱, 再套上一个叫 apoB 的外壳蛋白, 做成一种叫 VLDL 的运输颗粒发进血里。发得多, 血里的甘油三酯就高。所以要降它, 得让这条装配线慢下来。
EPA 和 DHA 进到肝细胞之后, 同时在三个地方拖慢这条线
原料不好用。 组装甘油三酯的那套酶, 对这两根弯折的长链并不顺手。能被装进货舱的量, 比普通脂肪酸少。把开关拨向烧掉。 肝细胞里有一个决定脂肪酸命运的开关 (PPARα): 是打包运走, 还是送进线粒体烧掉。omega-3 把它往烧掉那边拨, 于是排队等着被打包的原料又少了一批。装不满的车不发。 货凑不够, 那个 apoB 外壳蛋白就会在原地被降解掉——车还没出厂就先拆了。
三条合起来是同一个结果: 肝脏往血里发的 VLDL 颗粒变少了。 血里的甘油三酯随之下来。
这也解释了剂量为什么必须那么高
注意这里要改的不是某一个反应的快慢, 而是一整个器官的装配线运转率。要做到这一点, 肝细胞里的 omega-3 浓度必须真的换过来——回到 EPA 与 DHA 那一幕的说法: 得先换膜、换库存。
日常保健那个量做不到, 所以降甘油三酯用的量是它的好几倍, 而且要连着吃上一段时间, 血脂才看得出变化。这不是厂家在加量卖货, 是机制本身要求的。
顺带解释另一件事: 为什么纯 EPA 制剂是药, 不是保健品
它用的量已经进到需要医生盯着的区间。同一个剂量既然高到能改变一个器官的行为, 就同时高到会带来别的后果——高剂量 omega-3 会拉长出血时间, 大型试验里也观察到过房颤增多 (见 EPA 与 DHA 那一幕的试验对照)。
能改变生理的剂量和会产生副作用的剂量, 永远是一起到来的。 这句话不只适用于鱼油——你在任何一个补剂上看到治疗量远高于保健量, 都可以先这样推一遍。
证据分层 · 逐条适应症
鱼油 / EPA + DHA 在心血管之外有其他循证适应症, 证据强度差别大。强证据 (A 级):
高甘油三酯 (TG > 500 mg/dL): EPA + DHA 2–4 g/天降 TG 20–50%icosapent ethyl (Vascepa) 4 g 加他汀, 高 TG 加 atherosclerotic cardiovascular disease: The plaque-clogged-artery family of disease — heart attack, stroke, peripheral artery disease. 患者 MACE 减少 25% (REDUCE-IT)孕期 DHA 200 mg+/天: 胎儿脑加视觉发育, ACOG 推荐
中等证据 (B 级):
类风湿性关节炎 (RA): 补 3-4 个月可减少晨僵 (SMD -0.43) 与 NSAID 用量 (SMD -0.40), 汇总 17 项 RCT (Goldberg 2007 meta)。⚠️ 那个 3-4 在论文里是疗程月数, 不是 g/天 —— 该文没有给出剂量数字重度抑郁辅助治疗: Liao 2019 meta 看到获益的是EPA 占配方 ≥ 60%、且 EPA 剂量 ≤ 1 g/天的那一档; 以 DHA 为主的配方没有。注意剂量那一条是上限不是下限 —— 这里加量不是杠杆干眼症: DREAM 试验 2018 显示没有显著获益 (此前小型研究曾乐观)
有争议、弱证据:
认知功能、阿尔茨海默预防: 多数 RCT 阴性 (Yurko-Mauro 2010 DHA 单用看到一点, 但 ADCS DHA 试验 — Quinn 2010 JAMA — 与 VITAL 都是阴性)儿童 ADHD: Bloch 2011 meta 显示小效应 (SMD ~ 0.31), 不是一线黄斑变性: AREDS2 显示加 ω-3 没有额外获益运动恢复: 减少肌肉酸痛证据有限过敏、哮喘: 早期母婴补充可能轻度降低后代过敏风险
没有证据、反向证据:
预防癌症: VITAL 阴性预防糖尿病: ASCEND 阴性变聪明抗衰老: 营销话术, 没有 RCT 支持
所以鱼油的真实定位:
特定患者 (高 TG / RA / 重度抑郁某些亚型) 的辅助治疗不吃鱼者的 ω-3 来源孕期 DHA 补充不是健康人保健万能补剂
4 questions before buying
If you've decided to supplement fish oil, these 4 questions avoid ~80% of bad products.1. What specific problem are you trying to solve? (indication)
'Cardiovascular wellness' without a specific diagnosis: eat fish first, not supplements; if you really want to, EPA + DHA 1 g/day is enoughHigh TG > 500: 2-4 g/dayPregnancy: DHA-dominant 200-500 mg/dayRA / arthritis: 3-4 g/day EPA + DHADepression adjunct: EPA-dominant formula (> 60% EPA), > 1 g/dayCan't answer? Don't buy
2. How much actual EPA + DHA is in this bottle?
Read the nutrition panel, not the headline on the front'1000 mg fish oil' ≠ '1000 mg ω-3' (see scene 1)Target: at least 500 mg EPA + DHA per capsule for a 'concentrated' product
3. Form (TG / rTG / EE)?
rTG or TG outperforms EE (30-50% absorption difference)EE form must be taken with a fatty mealVascepa (icosapent ethyl) is EE but pure EPA at 4 g — prescription use, not wellness
4. Oxidation (TOTOX) + certification?
IFOS 5-star / GOED certificationTOTOX < 10 is excellentFishy taste / nausea / burps: already oxidized — return itRefrigeration + brown glass bottle > clear plasticUse within 2-3 months after opening
3 red flags — put it down immediately:
'Deep-sea fish oil' with no EPA / DHA milligram breakdown on the label: deceptive'X dollars for 100 caps' suspiciously cheap: usually EE form with high oxidation'Beauty / anti-aging / makes-you-smarter' marketing: outside the evidence base
liao-2019-omega3-depression-metagoldberg-2007-omega3-joint-pain-metaquinn-2010-adcs-dha
References · 6
- National Institutes of Health, Office of Dietary Supplements. (2023). Omega-3 Fatty Acids — Fact Sheet for Health Professionals. ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional
- Bhatt, D. L., et al. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). NEJM, 380(1), 11–22. 10.1056/NEJMoa1812792
- Manson, J. E., et al. (2019). Marine n-3 fatty acids and prevention of cardiovascular disease and cancer (VITAL). NEJM, 380(1), 23–32. 10.1056/NEJMoa1811403
- Mozaffarian, D., & Wu, J. H. Y. (2011). Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. Journal of the American College of Cardiology, 58(20), 2047–2067. 10.1016/j.jacc.2011.06.063
- Sacks, F. M., Lichtenstein, A. H., Wu, J. H. Y., Appel, L. J., Creager, M. A., Kris-Etherton, P. M., et al. (2017). Dietary fats and cardiovascular disease: A presidential advisory from the American Heart Association. Circulation, 136(3), e1-e23. Coconut oil is ~82% saturated; the AHA advises against its use because it raises LDL-C with no known offsetting favorable effect, and recommends replacing saturated with unsaturated fat. 10.1161/CIR.0000000000000510
- Burdge, G. C. (2006). Metabolism of α-linolenic acid in humans. Prostaglandins, Leukotrienes and Essential Fatty Acids, 75(3), 161–168. 10.1016/j.plefa.2006.05.013